KRYS Relative Valuation
KRYS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KRYS is overvalued; if below, it's undervalued.
Historical Valuation
Krystal Biotech Inc (KRYS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.84 is considered Undervalued compared with the five-year average of -18.77. The fair price of Krystal Biotech Inc (KRYS) is between 592.14 to 637.85 according to relative valuation methord. Compared to the current price of 147.49 USD , Krystal Biotech Inc is Undervalued By 75.09%.
Relative Value
Fair Zone
592.14-637.85
Current Price：147.49
75.09%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
4.41
P/B
Median3y
4.90
Median5y
4.26
2.98
FCF Yield
Median3y
-3.19
Median5y
-3.90
Competitors Valuation Multiple
The average P/S ratio for KRYS's competitors is 137.19, providing a benchmark for relative valuation. Krystal Biotech Inc Corp (KRYS) exhibits a P/S ratio of 9.84, which is -92.83% above the industry average. Given its robust revenue growth of 94.88%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Krystal Biotech Inc (KRYS) currently overvalued or undervalued?
What is Krystal Biotech Inc (KRYS) fair value?
How does KRYS's valuation metrics compare to the industry average?
What is the current P/B ratio for Krystal Biotech Inc (KRYS) as of Jul 19 2025?
What is the current FCF Yield for Krystal Biotech Inc (KRYS) as of Jul 19 2025?
What is the current Forward P/E ratio for Krystal Biotech Inc (KRYS) as of Jul 19 2025?